Ceftaroline and Daptomycin Combination Antibiotic Therapy for a Methicillin-Resistant Staphylococcus Aureus Liver...

Area of Science:

• Neonatal Intensive Care Unit (NICU) infections
• Bacterial pathogenesis and treatment
• Pediatric infectious diseases

Background:

• Staphylococcus aureus is a frequent cause of NICU infections.
• Methicillin-resistant Staphylococcus aureus (MRSA) infections are challenging to treat, especially in neonates.
• Limited data exist on treating MRSA abscesses in the neonatal population.

Purpose of the Study:

• To report a case of successful combination therapy for MRSA hepatic abscesses and infected thrombus in a premature infant.
• To highlight the potential efficacy of daptomycin plus ceftaroline in neonatal MRSA infections.
• To underscore the need for further research into combination therapy for neonatal MRSA.

Main Methods:

• A premature infant (30 weeks gestation) with MRSA hepatic abscesses and infected thrombus was treated.
• Initial treatment with daptomycin monotherapy failed, showing increased abscess size.
• Treatment was switched to intravenous daptomycin plus ceftaroline combination therapy for 18 days.

Main Results:

• Combination therapy with daptomycin and ceftaroline led to complete resolution of hepatic abscesses.
• Abscess resolution was confirmed by ultrasonography within 3 weeks of initiating combination therapy.
• The patient's MRSA infection was successfully managed with the combined antibiotic regimen.

Conclusions:

• Intravenous daptomycin plus ceftaroline combination therapy can be effective for treating refractory MRSA infections in premature infants.
• This case suggests a potential therapeutic option for complex neonatal MRSA cases.
• Further research is essential to establish optimal combination therapy protocols for neonatal MRSA infections.